Related scientific articles (all)

International study on inter-reader variability for circulating tumor cells in breast cancer.

Authors : Ignatiadis M, Riethdorf S, Bidard FC, Vaucher I, Khazour M, Rothé F, Metallo J, Rouas G, Payne RE, Coombes RC, Teufel I, Andergassen U, Apostolaki S, Politaki E, Mavroudis D, Bessi S, Pestrin M, Di Leo A, Campion M, Reinholz M, Perez E, Piccart-Gebhart M, Borgen E, Naume B, Jimenez J, Aura CM, Zorzino L, Cassatella MC, Sandri MT, Mostert B, Sleijfer S, Kraan J, Janni W, Fehm T, Rack B, Terstappen L, Repollet M, Pierga JY, Miller C, Sotiriou C, Michiels S, Pantel K
Year : 2014
Journal : Breast Cancer Res
Volume : 16(2)
Pages : R43

Impact of tumor sequencing on the use of anticancer drugs.

Authors : Thomas F, Desmedt C, Aftimos P, Awada A
Year : 2014
Journal : Curr Opin Oncol
Volume : 26(3)
Pages : 347-56

Tumor infiltrating lymphocytes is prognostic and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial.

Authors : Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D, Kellokumpu-Lehtinen PL, Bono P, Kataja V, Desmedt C, Piccart-Gebhart M, Loibl S, Denkert C, Smyth MJ, Joensuu H, Sotiriou C
Year : 2014
Journal : Ann Oncol
Volume : 25(8)
Pages : 1544-50

Infrared imaging in breast cancer: automated tissue component recognition and spectral characterization of breast cancer cells as well as the tumor microenvironment.

Authors : Benard A, Desmedt C, Smolina M, Szternfeld P, Verdonck M, Rouas G, Kheddoumi N, Rothé F, Larsimont D, Sotiriou C, Goormaghtigh E
Year : 2014
Journal : Analyst
Volume : 139(5)
Pages : 1044-56

TP53 mutation-correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53-mutated breast cancers.

Authors : Bottai G, Lehmann-Che J, Kéri G, Orfi L, Iwamoto T, Desmedt C, Bianchini G, Turner NC, de Thè H, André F, Sotiriou C, Hortobagyi GN, Di Leo A, Pusztai L, Santarpia L
Year : 2014
Journal : Mol oncol
Volume : 8(3)
Pages : 508-19

Informed consent, biobank research, and locality: perceptions of breast cancer patients in three European countries.

Authors : Petersen I, Desmedt C, Harris A, Buffa F, Kollek R
Year : 2014
Journal : J Empir Res Hum Res Ethics
Volume : 9(3)
Pages : 48-55

Transfer of clinically relevant gene expression signatures in breast cancer: from Affymetrix microarray to Illumina RNA-Sequencing technology.

Authors : Fumagalli D, Blanchet-Cohen A, Brown D, Desmedt C, Gacquer D, Michiels S, Rothé F, Majjaj S, Salgado R, Larsimont D, Ignatiadis M, Maetens M, Piccart-Gebhart M, Detours V, Sotiriou C, Haibe-Kains B
Year : 2014
Journal : BMC Genomics
Volume : 15(1)
Pages : 1008

Deciphering clonality in aneuploid tumors using SNP array and sequencing data.

Authors : Lönnstedt IM, Caramia F, Li J, Fumagalli D, Salgado R, Rowan A, Salm M, Kanu N, Savas P, Horswell S, Gade S, Loibl S, Neven P, Sotiriou C, Swanton C, Loi S, Speed TP
Year : 2014
Journal : Genome Biol.
Volume : 15(9)
Pages : 470

Comparison of the prognostic value of genomic grade index, Ki67 expression and mitotic activity index in early node-positive breast cancer patients.

Authors : Bertucci F, Finetti P, Roche H, Le Doussal JM, Marisa L, Martin AL, Lacroix-Triki M, Blanc-Fournier C, Jacquemier J, Peyro-Saint-Paul H, Viens P, Sotiriou C, Birnbaum D, Penault-Llorca F
Year : 2013
Journal : Ann Oncol
Volume : 24(3)
Pages : 625-32

Molecular Pathways: Involvement of Immune Pathways in the Therapeutic Response and Outcome in Breast Cancer.

Authors : Andre F, Dieci MV, Dubsky P, Sotiriou C, Curigliano G, Denkert C, Loi S
Year : 2013
Journal : Clin Cancer Res
Volume : 19(1)
Pages : 28-33

Distinct tumor protein p53 mutants in breast cancer subgroups.

Authors : Dumay A, Feugeas JP, Wittmer E, Lehmann-Che J, Bertheau P, Espié M, Plassa LF, Cottu P, Marty M, André F, Sotiriou C, Pusztai L, de Thé H
Year : 2013
Journal : Int. J. Cancer
Volume : 132(5)
Pages : 1227-31

Pertuzumab: new hope for patients with HER2-positive breast cancer.

Authors : Capelan M, Pugliano L, de Azambuja E, Bozovic I, Saini KS, Sotiriou C, Loi S, Piccart-Gebhart M
Year : 2013
Journal : Ann Oncol
Volume : 24(2)
Pages : 273-82

Genomic Grade Index (GGI): feasibility in routine practice and impact on treatment decisions in early breast cancer.

Authors : Metzger-Filho O, Catteau A, Michiels S, Buyse M, Ignatiadis M, Saini KS, de Azambuja E, Fasolo V, Naji S, Canon JL, Delrée P, Coibion M, Cusumano P, Jossa V, Kains JP, Larsimont D, Richard V, Faverly D, Cornez N, Vuylsteke P, Vanderschueren B, Peyro-Saint-Paul H, Piccart-Gebhart M, Sotiriou C
Year : 2013
Journal : PLoS One
Volume : 8(8)
Pages : e66848

Genomic grade adds prognostic value in invasive lobular carcinoma.

Authors : Metzger-Filho O, Michiels S, Bertucci F, Catteau A, Salgado R, Galant C, Fumagalli D, Singhal SK, Desmedt C, Ignatiadis M, Sandy H, Finetti P, Birnbaum D, Saini KS, Berlière M, Veys I, de Azambuja E, Bozovic I, Peyro-Saint-Paul H, Larsimont D, Piccart-Gebhart M, Sotiriou C
Year : 2013
Journal : Ann Oncol
Volume : 24(2)
Pages : 377-84

Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers.

Authors : Bianchini G, Pusztai L, Karn T, Iwamoto T, Rody A, Kelly CM, Müller V, Schmidt M, Qi Y, Holtrich U, Becker S, Santarpia L, Fasolo A, Del Conte G, Zambetti M, Sotiriou C, Haibe-Kains B, Symmans WF, Gianni L
Year : 2013
Journal : Breast Cancer Res
Volume : 15(5)
Pages : R86

TOP2A protein by quantitative immunofluorescence as a predictor of response to epirubicin in the neoadjuvant treatment of breast cancer.

Authors : Moretti E, Desmedt C, Biagioni C, Regan MM, Oakman C, Larsimont D, Galardi F, Piccart-Gebhart M, Sotiriou C, Rimm DL, Di Leo A
Year : 2013
Journal : Future Oncol
Volume : 9(10)
Pages : 1477-87

Circulating tumor cells and response to neoadjuvant paclitaxel and HER2-targeted therapy: A sub-study from the NeoALTTO phase III trial.

Authors : Azim HA, Rothé F, Aura CM, Bavington M, Maetens M, Rouas G, Gebhart G, Gamez C, Eidtmann H, Baselga J, Piccart-Gebhart M, Ellis C, Vuylsteke P, Cure H, Domont J, Ferro A, Toral-Peña JC, de Azambuja E, Sotiriou C, Di Cosimo S, Ignatiadis M
Year : 2013
Journal : Breast
Volume : 22(6)
Pages : 1060-5

Phase I trial combining temozolomide plus lapatinib for the treatment of brain metastases in patients with HER2-positive metastatic breast cancer: the LAPTEM trial.

Authors : de Azambuja E, Zardavas D, Lemort M, Rossari J, Moulin C, Buttice A, Dhondt V, Lebrun F, Lalami Y, Cardoso F, Sotiriou C, Gil T, Devriendt D, Paesmans M, Piccart-Gebhart M, Awada A
Year : 2013
Journal : Ann Oncol
Volume : 24(12)
Pages : 2985-9

Genomic grade adds prognostic value in invasive lobular carcinoma.

Authors : Metzger-Filho O, Michiels S, Bertucci F, Catteau A, Salgado R, Galant C, Fumagalli D, Singhal SK, Desmedt C, Ignatiadis M, Haussy S, Finetti P, Birnbaum D, Saini KS, Berlière M, Veys I, de Azambuja E, Bozovic I, Peyro-Saint-Paul H, Larsimont D, Piccart-Gebhart M, Sotiriou C
Year : 2013
Journal : Ann Oncol
Volume : 24
Pages : 377-384

Somatic Mutation Profiling and Associations With Prognosis and Trastuzumab Benefit in Early Breast Cancer.

Authors : Loi S, Michiels S, Lambrechts D, Fumagalli D, Claes B, Kellokumpu-Lehtinen PL, Bono P, Kataja V, Piccart-Gebhart M, Joensuu H, Sotiriou C
Year : 2013
Journal : J. Natl. Cancer Inst.
Volume : 105(13)
Pages : 960-967